**Supplementary Appendix 2 : Questionnaires**

The DLQI is a validated QoL questionnaire specific for skin conditions1*.* It contains 10 questions referring to the last week and covers the following aspects: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Each question is answered by "not at all", "only a little", "quite a lot" and "very much" and is scored 0, 1, 2 or 3, respectively. The sum score ranges from 0 (no impairment of life quality) to 30 (maximum impairment)2.

The Skindex-29 is a validated dermatology-specific QoL instrument3. It consists of 29 items that explore three domains: Symptoms, Functioni

ng and Emotions. Items refer to the previous 4-week period and are answered on a 5-point scale, from «never» to «all the time». All responses are transformed to a linear scale ranging from 0 (no effect) to 100 (maximum possible effect). The scale score is computed by averaging patient’s responses to each item, with a higher score signifying greater impairment4.

The RAND 36-item Health Survey (SF-36) is a widely used generic QoL instrument that has been validated5. It contains 8 domains: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perception. Each of the 8 domains ranges in score from 0 to 100, in which higher values show better QoL6,7.

The EQ-5D is a generic self-administered health status questionnaire that has been validated for adult age groups8. It consists of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression9,10. Each dimension can be rated at one of three levels (no problem, some problems, extreme problems). Combinations of these levels create 243 possible health states. We converted these health states to a single summary index by using a European EQ-5D visual analogue scale (VAS)-based set of values, where a higher score indicates higher QoL11. In addition, the EQ-5D contains also a 20 cm VAS that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state), where respondents are asked to rate their current health state.

The Beck Depression Inventory (BDI) is a self-completed validated questionnaire measuring depressive symptoms regardless of health status12. It includes 21 items, each scored 0-3. Total score ranges from 0 – 63 with higher scores indicating more severe depressive symptoms. Patients were classified as having no or minimal (score 0-13), mild (score 14-19), moderate (score 20-28) or severe (score 29-63) depression13

The disease severity was assessed by a clinician using the validated scoring systems Psoriasis Area and Severity Index (PASI) for psoriasis and Eczema Area and Severity Index (EASI) for AD, with a score range from 0 (no disease) to 72 (maximal disease)14-17.

References

1. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Lebensqualität bei haut-erkrankungen: vergleich verschiedener lebensqualitäts-fragebögen bei psoriasis und atopischer dermatitis. *Der Hautarzt*. 1999;50(10):715-722.

2. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19(3):210-216.

3. Augustin M, Wenninger K, Amon U, et al. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. *Dermatology (Basel)*. 2004;209(1):14-20. doi:10.1159/000078581.

4. Chren M-M. The Skindex instruments to measure the effects of skin disease on quality of life. *Dermatol Clin*. 2012;30(2):231-6, xiii. doi:10.1016/j.det.2011.11.003.

5. Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. *Soc Sci Med*. 1995;41(10):1359-1366. doi:10.1016/0277-9536(95)00115-n.

6. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. *Medical care*. 1992:473-483.

7. Hays RD, Shapiro MF. An overview of generic health-related quality of life measures for HIV research. *Quality of life research*. 1992;1(2):91-97.

8. Graf J-M, Claes C, Greiner W, Uber A. Die deutsche Version des EuroQol-Fragebogens. *Zeitschrift für Gesundheitswissenschaften= Journal of public health*. 1998;6(1):3-20.

9. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. *Health policy (Amsterdam, Netherlands)*. 1990;16(3):199.

10. Brooks R, Group E. EuroQol: the current state of play. *Health policy (Amsterdam, Netherlands)*. 1996;37(1):53-72.

11. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. *The European Journal of Health Economics, formerly: HEPAC*. 2003;4(3):222-231.

12. Kühner C, Bürger C, Keller F, Hautzinger M. Reliability and validity of the revised Beck Depression Inventory (BDI-II). Results from German samples. *Nervenarzt*. 2007;78(6):651-656.

13. Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. *Journal of personality assessment*. 1996;67(3):588-597.

14. Rehal B, Armstrong AW, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. *PLoS ONE*. 2011;6(4):e17520. doi:10.1371/journal.pone.0017520.

15. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. *J Eur Acad Dermatol Venereol*. 2010;24 Suppl 2:10-16. doi:10.1111/j.1468-3083.2009.03562.x.

16. Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. *Dermatology*. 1978;157(4):238-244.

17. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. *Experimental dermatology*. 2001;10(1):11-18.